Company overview
AMSBIO provides cutting-edge life science reagents and services, including specialist antibodies, peptides, recombinant proteins, and extracellular matrices for cell motility, migration, invasion, and proliferation studies. The company supports key research areas such as oncology, regenerative medicine, stem cell biology, glycomics, and cytotoxicity screening with molecular detection reagents and biorepository products like tissue DNA, RNA, and proteins. Founded in 1987, AMSBIO partners globally with offices in the UK, US, Netherlands, and Switzerland to accelerate discovery in medical, nutrition, cosmetics, and energy industries.
Industry categories: Life Science Reagents. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.amsbio.com
- Categories
- Life Science Reagents
- Markets served
- United States & Americas
- Keywords
- amsbio, cell culture reagents, extracellular matrix, stem cell products, oncology research, recombinant proteins
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What products does AMSBIO offer for cell culture and research?
- AMSBIO offers specialist antibodies, peptides, recombinant proteins, extracellular matrices, molecular detection reagents, and biorepository products including tissue DNA, RNA, proteins, and microarrays for applications in oncology, regenerative medicine, stem cell biology, and more.
- In which geographies does AMSBIO operate?
- AMSBIO is active worldwide with offices in the UK, US, the Netherlands, and Switzerland, providing global partnerships for life science reagents and services.
- What are AMSBIO's key capabilities in life sciences?
- AMSBIO excels in tailoring cell systems for enhanced screening, cell motility studies, and providing high-titer lentiviral particles, supporting innovative methods in research, development, and biopharma applications.
Related editorial coverage
- Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
